Good morning. CJC-1295 and Ipamorelin are the two most co-searched peptides in the PPL index, particularly among readers in their forties and fifties. This week one of them moved in price. The reason is upstream, and it matters for how you read the market going forward.
What the price data showed
CJC-1295 5mg vials climbed roughly 8% across the vendors we index over the last 30 days. Ipamorelin held flat across the same period. The practical effect: the per-mg cost of acquiring both together rose, driven entirely by the CJC-1295 side.
The likely cause is synthesis complexity. CJC-1295 is a 30-amino-acid peptide with a drug affinity complex modification that extends its half-life significantly. Longer, modified peptides cost more to manufacture and have been less price-stable than shorter, simpler compounds. Whether this 8% move is a temporary squeeze or a new floor is not yet clear. We will watch it through June.
When two research peptides are almost always purchased together, a price move in one is effectively a price move in both.
What the research says
CJC-1295 is a growth hormone-releasing hormone analog. Ipamorelin is a growth hormone-releasing peptide. They act on different receptors but toward the same end: stimulating the pituitary to release more of the body's own growth hormone, in a pulse that more closely resembles natural rhythms than older compounds in this class.
Researchers use them together because neither alone produces as robust a response as both together. The CJC-1295 extends the signal window; the Ipamorelin amplifies the peak. That synergy is the rationale behind co-use in the literature.
The studies look primarily at lean tissue preservation, sleep architecture (growth hormone secretion and deep sleep appear bidirectional), skin collagen production, and recovery. Most of this evidence comes from animal models and small human trials. The human studies are limited in size, duration, and the populations they cover. That gap is worth naming plainly.
A note for women researching this
Growth hormone declines with age in everyone. There is evidence the decline is more pronounced after perimenopause, and that context is part of why these two peptides dominate searches from women in their forties and fifties. The research examines growth hormone secretagogues for their potential effects on body composition, sleep quality, and skin, which are all areas where the perimenopause transition creates real changes.
What the research does not yet provide: a well-powered, long-term human trial in perimenopausal women. What is studied in younger men, or in animals, may or may not translate. CJC-1295 and Ipamorelin are research peptides. They are not FDA-approved treatments for perimenopause or any related condition. That is not a dismissal of the research. It is an honest description of where it currently stands.
Reply if you spotted a vendor move we missed. Next week: the vial-size math we have been promising since No. 01.